Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study
Rattachement africain : tr. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Purpose: The prognostic value of cetuximab-related electrolyte disturbances in metastatic colorectal cancer (CRC) remains unclear. The available reports on the prognostic effect of hypomagnesemia are controversial, while there are no comprehensive analyses regarding hypokalemia. This study aimed to evaluate the impact of hypomagnesemia and hypokalemia on treatment outcomes in patients with RAS/RAF wild-type metastatic CRC receiving first-line cetuximab-based therapy. Patients and Methods: We retrospectively analysed 305 patients treated across seven oncology centers between March 2013 and December 2024. Patients with baseline renal insufficiency or pre-existing electrolyte disturbance were excluded. Serum magnesium and potassium levels were assessed from the initiation of cetuximab until one month after its discontinuation. Results: There was one patient with missing magnesium levels and one patient with missing potassium levels. Three-hundred and four patients were available for the final analyses (n=304). Hypomagnesemia and hypokalemia occurred in 29.9% and 20.7% of the patients, respectively. Neither hypomagnesemia nor hypokalemia was significantly associated with progression-free survival (PFS) (11.9 vs 11.7 months for each; p =0.528 and p =0.327) or overall survival (OS) (25.3 vs 27.9 months; p =0.705 and 22.0 vs 28.8 months; p =0.824, respectively). Hypokalemia was correlated with a higher disease control rate (96.8% vs 87.1%, p = 0.028). In multivariate analyses, only metastatic burden (≥ 2 sites) independently associated with inferior outcomes for both PFS (HR 1.61, 95% CI 1.25– 2.08, p < 0.001) and OS (HR 1.77, 95% CI 1.31– 2.39, p < 0.001). Conclusion: Hypomagnesemia and hypokalemia did not significantly impact survival outcomes despite previous studies indicating otherwise. Moreover, hypokalemia was linked to improved disease control. These results provide incremental evidence regarding the clinical relevance of electrolyte disturbances, particularly hypokalemia, and highlight the need for prospective studies to clarify their prognostic and predictive significance. Keywords: colorectal cancer, cetuximab, hypomagnesemia, hypokalemia
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study
- Date Crossref
- 01/01/2026
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Antalya Eğitim ve Araştırma Hastanesi pays non établi dans la noticeÉtablissement de santé
-
Pamukkale University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Bursa Uludağ Üni̇versi̇tesi̇ pays non établi dans la noticeUniversité ou école supérieure
-
Necmettin Erbakan University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Dokuz Eylül University Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Medical Park Gaziantep Hospital pays non établi dans la noticeÉtablissement de santé
-
Izmir University pays non établi dans la noticeUniversité ou école supérieure
-
Antalya Training and Research Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Uludağ University Hospital Department of Medical Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Gaziantep City Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Izmir City Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
Antalya Eğitim ve Araştırma Hastanesi, Department of Medical Oncology — Pamukkale University et Bursa Uludağ Üni̇versi̇tesi̇, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.